Johnson & Johnson says Cypher stent outperforms Taxus in small vessel trial

New York, Feb. 2 - Johnson & Johnson's Cordis Corp. subsidiary said its Cypher stent outperformed the Taxus stent on three measures in a study in small coronary vessels.

The randomized clinical trial found Cypher did better on late lumen loss - the primary endpoint - restenosis and target lesion revascularization.

The results were from a follow up at 12 months. Included in the study were 360 patients randomly selected for treatment with either drug-eluting stent who had challenging blockages in vessels with an average diameter size of less than 2.80 millimeters.

Small vessel diameter has been identified as an important predictor of restenosis (reblockage) after treatment with a coronary stent, Cordis said.

Cordis noted that other small vessel trials have also shown positive results for Cypher.

"The high standards of this independently conducted prospective, randomized study provide a true measurement of drug-eluting stent performance in this challenging patient population," stated Dennis Donohoe, worldwide vice president, clinical and regulatory affairs at Cordis, in a news release.

"Positive clinical outcomes such as the ones seen in this trial and others are testament to sirolimus, the drug used on the Cypher Stent and its mechanism of action, which provide physicians with additional confidence in every case they treat."

Johnson & Johnson is a New Brunswick, N.J., manufacturer of health care products.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.